Robert A. Somer
- Oncology top 5%
- Cancer Treatment and Pharmacology 6
- Lung Cancer Research Studies 4
- HER2/EGFR in Cancer Research 4
- Cancer Risks and Factors 3
- Otorhinolaryngology top 5%
- Cancer Research top 10%
-
- Lung Cancer Treatments and Mutations 7
- Brain Metastases and Treatment 4
- Prostate Cancer Treatment and Research 4
- Immunology top 10%
-
- Bladder and Urothelial Cancer Treatments 3
Robert A. Somer
33 papers receiving 1.2k citations
Hit Papers
Peers
Comparison fields: 5 of 73
- Oncology 946
- Otorhinolaryngology 67
- Cancer Research 220
- Pulmonary and Respiratory Medicine 417
- Immunology 255
Countries citing papers authored by Robert A. Somer
This map shows the geographic impact of Robert A. Somer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert A. Somer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert A. Somer more than expected).
Fields of papers citing papers by Robert A. Somer
This network shows the impact of papers produced by Robert A. Somer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert A. Somer. The network helps show where Robert A. Somer may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Robert A. Somer, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 1 | |
| 2 | 2023 | 6 | |
| 3 | 2019 | 11 | |
| 4 | Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor studybreakdown → | 2017 | 581 |
| 5 | 2017 | 24 | |
| 6 | 2017 | 3 | |
| 7 | 2017 | 34 | |
| 8 | 2016 | 1 | |
| 9 | 2016 | 9 | |
| 10 | 2016 | 2 | |
| 11 | 2013 | 15 | |
| 12 | 2012 | 86 | |
| 13 | 2012 | 19 | |
| 14 | 2012 | 55 | |
| 15 | 2012 | 33 | |
| 16 | 2011 | 17 | |
| 17 | 2008 | 23 | |
| 18 | 2007 | 7 | |
| 19 | 2004 | 95 | |
| 20 | 2002 | 32 |
About Robert A. Somer
Robert A. Somer is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine, having authored 34 papers that have together received 1.3k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (7 papers), Cancer Treatment and Pharmacology (6 papers), Brain Metastases and Treatment (4 papers), Lung Cancer Research Studies (4 papers), HER2/EGFR in Cancer Research (4 papers), Prostate Cancer Treatment and Research (4 papers), Cancer Risks and Factors (3 papers) and Bladder and Urothelial Cancer Treatments (3 papers). The work is most often cited by research in Oncology (946 citations), Otorhinolaryngology (67 citations) and Cancer Research (220 citations). Robert A. Somer has collaborated with scholars based in United States, United Kingdom and Germany. Frequent co-authors include Elyce Cardonick, Guy Jérusalem, István Takács, Petros Nikolinakos, Jayne S. Gurtler, Luc Dirix, Martin Šmakal, W. Jeff Edenfield, Erika Hamilton and Marc E. Lippman. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Cancer Research, The Oncologist and Clinical Genitourinary Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.